NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease

January 22, 2025

T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated diffuse large B-cell lymphoma (DLBCL). Given its efficacy in the post-CAR T-cell therapy setting, bispecific T-cell engager therapy has the potential to fulfill the unmet clinical need of patients with DLBCL that is refractory to multiple prior therapies including CAR T-cell therapy. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit associated with T-cell engager therapy using bispecific antibodies.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants/associates, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the rationale for the use of bispecific T-cell antibodies in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). 
  • Review the safety and efficacy data from clinical trials that have evaluated bispecific T-cell antibodies in patients with relapsed/refractory DLBCL.
  • Identify the adverse events of special interest (AESI) associated with bispecific T-cell antibodies and develop an appropriate supportive care intervention for the management of AESI.

You may also be interested in

Archived Monthly Oncology Tumor Boards: B-Cell Lymphomas: Histologic Transformation of Indolent Lymphomas
Learn about the challenges associated with the management of transformed indolent lymphomas and the recent advances in management to help you to incorporate novel therapies into routine clinical practice in the appropriate patient population to improve clinical outcomes.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Coherus BioSciences
  • Eisai Inc.
  • Genentech, a member of the Roche Group
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Novartis
  • Sanofi

This activity is supported by independent educational grants from:

  • Daiichi Sankyo
  • Merck & Co., Inc., Rahway, NJ, USA

This is activity is supported by independent medical education grants from:

  • AbbVie
  • GSK
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
11/14/2024
Course expires: 
04/27/2025
Event starts: 
01/22/2025 - 3:00pm EST
Event ends: 
01/22/2025 - 4:00pm EST
Cost:
$0.00
Part of: 
NCCN Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care
Add to calendar: 

L. Elizabeth Budde, MD, PhD
City of Hope National Medical Center

Lauren Clermont, DNP, NP-C, AOCNP, BMTCN
City of Hope National Medical Center

Stacy Pak, PharmD, BCOP
City of Hope National Medical Center

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Full disclosure of faculty relationships will be made prior to the activity.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: TBD

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this live webinar.

This webinar will be presented live one time only on Wednesday, January 22, 2025, from 3:00 – 4:00 PM EST (UTC -5). To adjust for other time zones, click here.

 

NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.

To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing